Xencor (XNCR) Upgraded to “Sell” by BidaskClub
BidaskClub upgraded shares of Xencor (NASDAQ:XNCR) from a strong sell rating to a sell rating in a research report released on Thursday.
Other equities research analysts also recently issued research reports about the company. Piper Jaffray Companies reissued a buy rating and set a $35.00 price objective on shares of Xencor in a report on Sunday, November 12th. Canaccord Genuity set a $36.00 price objective on Xencor and gave the company a buy rating in a report on Monday, October 23rd. ValuEngine raised Xencor from a sell rating to a hold rating in a report on Friday, September 1st. Zacks Investment Research raised Xencor from a sell rating to a hold rating in a report on Wednesday, November 22nd. Finally, Cantor Fitzgerald started coverage on Xencor in a report on Wednesday, November 29th. They set an overweight rating and a $33.00 target price on the stock. Two research analysts have rated the stock with a sell rating, three have given a hold rating and four have assigned a buy rating to the stock. Xencor presently has an average rating of Hold and an average price target of $30.80.
Shares of Xencor (NASDAQ:XNCR) opened at $22.35 on Thursday. Xencor has a twelve month low of $18.55 and a twelve month high of $28.64.
In other news, major shareholder John S. Stafford III bought 3,400 shares of the firm’s stock in a transaction that occurred on Wednesday, November 8th. The stock was acquired at an average cost of $19.89 per share, with a total value of $67,626.00. The purchase was disclosed in a legal filing with the SEC, which is available through this link. Also, major shareholder John S. Stafford III bought 24,653 shares of the firm’s stock in a transaction that occurred on Wednesday, October 25th. The stock was purchased at an average cost of $20.01 per share, with a total value of $493,306.53. The disclosure for this purchase can be found here. Over the last three months, insiders bought 263,105 shares of company stock valued at $5,206,858. Corporate insiders own 4.14% of the company’s stock.
A number of institutional investors have recently modified their holdings of the stock. FMR LLC increased its holdings in Xencor by 77.7% during the 2nd quarter. FMR LLC now owns 6,690,258 shares of the biopharmaceutical company’s stock worth $141,232,000 after purchasing an additional 2,924,510 shares in the last quarter. Vanguard Group Inc. lifted its stake in Xencor by 5.6% in the second quarter. Vanguard Group Inc. now owns 1,701,209 shares of the biopharmaceutical company’s stock valued at $35,913,000 after purchasing an additional 90,094 shares during the last quarter. State Street Corp lifted its stake in Xencor by 11.1% in the second quarter. State Street Corp now owns 1,103,455 shares of the biopharmaceutical company’s stock valued at $23,295,000 after purchasing an additional 110,474 shares during the last quarter. Northern Trust Corp lifted its stake in Xencor by 6.6% in the second quarter. Northern Trust Corp now owns 498,616 shares of the biopharmaceutical company’s stock valued at $10,527,000 after purchasing an additional 30,715 shares during the last quarter. Finally, Teachers Advisors LLC lifted its stake in Xencor by 1.9% in the second quarter. Teachers Advisors LLC now owns 330,042 shares of the biopharmaceutical company’s stock valued at $6,967,000 after purchasing an additional 6,260 shares during the last quarter. 77.62% of the stock is owned by institutional investors and hedge funds.
COPYRIGHT VIOLATION NOTICE: “Xencor (XNCR) Upgraded to “Sell” by BidaskClub” was first posted by Watch List News and is owned by of Watch List News. If you are viewing this article on another website, it was copied illegally and reposted in violation of United States and international copyright laws. The correct version of this article can be accessed at https://www.watchlistnews.com/xencor-xncr-upgraded-to-sell-by-bidaskclub/1757385.html.
Xencor Company Profile
Xencor, Inc is a clinical-stage biopharmaceutical company. The Company is focused on discovering and developing engineered monoclonal antibodies to treat severe and life threatening diseases. It has developed two clinical-stage product candidates, using its Immune Inhibitor Fc platform: XmAb5871, which is in two Phase II trials and is being developed for autoimmune disease, and XmAb7195, which is in a Phase I trial and is being developed for asthma and allergic diseases.
Receive News & Ratings for Xencor Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Xencor Inc. and related companies with Analyst Ratings Network's FREE daily email newsletter.